FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078991231> ?p ?o ?g. }

• W2078991231 endingPage "47" @default.
• W2078991231 startingPage "39" @default.
• W2078991231 abstract "Conocer la prevalencia de los factores de riesgo vascular (FRCV) y de enfermedad cardiovascular, y evaluar el tratamiento de los mismos en una población multicéntrica de pacientes pluripatológicos (PPP). Estudio longitudinal en 36 hospitales (febrero de 2007 – junio de 2008). Análisis descriptivo de los FRCV y enfermedades cardiovasculares, y de la prescripción de fármacos, así como de los factores asociados a la polifarmacia. Se incluyeron 1.632 PPP, con una edad media de 77,9 ± 9,8 años. La prevalencia de FRV fue: hipertensión arterial 71,8%; obesidad 70,5%; diabetes mellitus 45,6% (36,4% con repercusión visceral); dislipemia 28,9% y tabaquismo 6,1%. La prevalencia de enfermedad cardiovascular fue: insuficiencia cardiaca 37%; cardiopatía isquémica 20,7% y ambas el 20,9%; enfermedad cerebrovascular 25,8%; y arteriopatía periférica sintomática 13,1%. La prevalencia de polifarmacia fue del 85,6% con un 63% de pacientes que recibían tratamiento hipolipemiante, 84% hipoglucemiante y 93% antihipertensivos, aunque solo el 28% de los pacientes con insuficiencia cardiaca tenían prescritos IECA/ARAII + betabloqueantes + diuréticos. Los factores asociados a la polifarmacia fueron la existencia de cardiopatía o insuficiencia renal crónica, el índice de Charlson, el menor deterioro en la valoración de las actividades instrumentales y el número de ingresos en los 12 meses previos. Los FRV y las enfermedades cardiovasculares presentaron un notable protagonismo en los PPP. A pesar de la alta prevalencia de polifarmacia se ha detectado tratamiento subóptimo en alguna de las condiciones analizadas. El impacto positivo de la intensificación de medidas de control de riesgo vascular en esta población debe ser evaluado. To analyze the prevalence of risk factors (RF) and cardiovascular diseases, and evaluate their treatment in a multicenter population of patients with multiple conditions (PMC). A longitudinal study including 36 Spanish hospitals (February 2007 - June 2008). Descriptive analysis of CVRF and cardiovascular diseases, and drug prescription profile and analysis of multidrug risk factors. Total PMCs included were 1,632, with a mean age of 77.9 ± 9.8 years. VRF prevalence was: hypertension 71. 8%, obesity 70.5%, diabetes mellitus 45.6% (36.4% of them with visceral damage), dyslipidemia 28.9% and smoking 6.1%. The prevalence of cardiovascular disease was heart failure: 37%. Ischemic heart disease, 20.7%, and both 20.9%, cerebrovascular disease 25%, and symptomatic peripheral arteriopathy in 13.1%. The prevalence of poly-drug treatment was 85.6% with 63% of patients receiving lipid lower drugs, 84% insulin or antidiabetics and 95% anti-hypertensive drugs, although only 28% of patients with heart failure had been prescribed ACE/ Angiotensin II-receptor-blockers + betablockers + diuretics. Factors associated with multi-drug treatment were heart diseases or chronic kidney failure, the Charlson index, the preservation of instrumental activities, and the number of hospital admissions in the last 12 months. Cardiovascular diseases and their risk factors had a significant role in the PMC population. In spite of the high prevalence of multi-drug treatment, suboptimal treatment was detected in some of the conditions evaluated. Intensifying risk control strategies for vascular and cardiovascular diseases should be evaluated specifically for this population." @default.
• W2078991231 created "2016-06-24" @default.
• W2078991231 creator A5006857965 @default.
• W2078991231 creator A5030911768 @default.
• W2078991231 creator A5032366692 @default.
• W2078991231 creator A5035264356 @default.
• W2078991231 creator A5039531093 @default.
• W2078991231 creator A5060229795 @default.
• W2078991231 creator A5061694005 @default.
• W2078991231 creator A5066917907 @default.
• W2078991231 creator A5067071270 @default.
• W2078991231 creator A5081948939 @default.
• W2078991231 date "2011-03-01" @default.
• W2078991231 modified "2023-10-16" @default.
• W2078991231 title "Riesgo cardiovascular y prescripción farmacológica en pacientes pluripatológicos" @default.
• W2078991231 cites W1971652050 @default.
• W2078991231 cites W1995779077 @default.
• W2078991231 cites W2000445173 @default.
• W2078991231 cites W2003972164 @default.
• W2078991231 cites W2007276450 @default.
• W2078991231 cites W2008843679 @default.
• W2078991231 cites W2021062883 @default.
• W2078991231 cites W2024450903 @default.
• W2078991231 cites W2024501220 @default.
• W2078991231 cites W2055701315 @default.
• W2078991231 cites W2067831298 @default.
• W2078991231 cites W2067868110 @default.
• W2078991231 cites W2086925949 @default.
• W2078991231 cites W2092129803 @default.
• W2078991231 cites W2097707527 @default.
• W2078991231 cites W2101674042 @default.
• W2078991231 cites W2103881469 @default.
• W2078991231 cites W2105095326 @default.
• W2078991231 cites W2117213460 @default.
• W2078991231 cites W2128122302 @default.
• W2078991231 cites W2128529067 @default.
• W2078991231 cites W2133416234 @default.
• W2078991231 cites W2159090766 @default.
• W2078991231 cites W2159730165 @default.
• W2078991231 cites W2165884492 @default.
• W2078991231 cites W2173153843 @default.
• W2078991231 cites W2177640000 @default.
• W2078991231 cites W2303651371 @default.
• W2078991231 cites W2322239518 @default.
• W2078991231 cites W2567772772 @default.
• W2078991231 cites W2626017884 @default.
• W2078991231 cites W2169742106 @default.
• W2078991231 doi "https://doi.org/10.1016/j.hipert.2011.03.001" @default.
• W2078991231 hasPublicationYear "2011" @default.
• W2078991231 type Work @default.
• W2078991231 sameAs 2078991231 @default.
• W2078991231 citedByCount "3" @default.
• W2078991231 countsByYear W20789912312012 @default.
• W2078991231 countsByYear W20789912312014 @default.
• W2078991231 crossrefType "journal-article" @default.
• W2078991231 hasAuthorship W2078991231A5006857965 @default.
• W2078991231 hasAuthorship W2078991231A5030911768 @default.
• W2078991231 hasAuthorship W2078991231A5032366692 @default.
• W2078991231 hasAuthorship W2078991231A5035264356 @default.
• W2078991231 hasAuthorship W2078991231A5039531093 @default.
• W2078991231 hasAuthorship W2078991231A5060229795 @default.
• W2078991231 hasAuthorship W2078991231A5061694005 @default.
• W2078991231 hasAuthorship W2078991231A5066917907 @default.
• W2078991231 hasAuthorship W2078991231A5067071270 @default.
• W2078991231 hasAuthorship W2078991231A5081948939 @default.
• W2078991231 hasConcept C29456083 @default.
• W2078991231 hasConcept C71924100 @default.
• W2078991231 hasConceptScore W2078991231C29456083 @default.
• W2078991231 hasConceptScore W2078991231C71924100 @default.
• W2078991231 hasIssue "2" @default.
• W2078991231 hasLocation W20789912311 @default.
• W2078991231 hasOpenAccess W2078991231 @default.
• W2078991231 hasPrimaryLocation W20789912311 @default.
• W2078991231 hasRelatedWork W1506200166 @default.
• W2078991231 hasRelatedWork W1995515455 @default.
• W2078991231 hasRelatedWork W1999344589 @default.
• W2078991231 hasRelatedWork W2039318446 @default.
• W2078991231 hasRelatedWork W2080531066 @default.
• W2078991231 hasRelatedWork W2748952813 @default.
• W2078991231 hasRelatedWork W2789448498 @default.
• W2078991231 hasRelatedWork W2899084033 @default.
• W2078991231 hasRelatedWork W3032375762 @default.
• W2078991231 hasRelatedWork W3108674512 @default.
• W2078991231 hasVolume "28" @default.
• W2078991231 isParatext "false" @default.
• W2078991231 isRetracted "false" @default.
• W2078991231 magId "2078991231" @default.
• W2078991231 workType "article" @default.